CytoMed Therapeutics Announces Press Release
Ticker: GDTC · Form: 6-K · Filed: Oct 7, 2024 · CIK: 1873093
| Field | Detail |
|---|---|
| Company | Cytomed Therapeutics LTD (GDTC) |
| Form Type | 6-K |
| Filed Date | Oct 7, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: press-release, filing-update
TL;DR
CytoMed dropped a press release on Oct 7, details TBD.
AI Summary
On October 7, 2024, CytoMed Therapeutics Limited announced the issuance of a press release. The filing does not contain further details about the content of this press release.
Why It Matters
This filing indicates a new announcement from CytoMed Therapeutics, which could contain material information for investors.
Risk Assessment
Risk Level: low — The filing is a routine 6-K report announcing a press release without providing specific material details.
Key Players & Entities
- CytoMed Therapeutics Limited (company) — Registrant
- October 7, 2024 (date) — Date of press release announcement
FAQ
What is the subject of the press release issued by CytoMed Therapeutics on October 7, 2024?
The filing states that CytoMed Therapeutics Limited issued a press release on October 7, 2024, but the content of the press release is not detailed within this Form 6-K.
What is the Commission File Number for CytoMed Therapeutics?
The Commission File Number for CytoMed Therapeutics is 001-41677.
Where is CytoMed Therapeutics Limited's principal executive office located?
CytoMed Therapeutics Limited's principal executive office is located at 1 Commonwealth Lane #08-22, Singapore 149544.
Has CytoMed Therapeutics Limited filed its annual report on Form 20-F?
Yes, the filing indicates that CytoMed Therapeutics Limited files its annual reports under cover of Form 20-F.
What was CytoMed Therapeutics' former company name?
CytoMed Therapeutics' former company name was CytoMed Therapeutics Pte. Ltd., with a date of name change on July 16, 2021.
Filing Stats: 509 words · 2 min read · ~2 pages · Grade level 15.3 · Accepted 2024-10-07 07:44:56
Filing Documents
- form6-k.htm (6-K) — 21KB
- ex99-1.htm (EX-99.1) — 24KB
- logo_001.jpg (GRAPHIC) — 44KB
- 0001493152-24-039643.txt ( ) — 107KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CytoMed Therapeutics Limited Date: October 7, 2024 By: /s/ CHOO Chee Kong CHOO Chee Kong Director and Chairman